Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12371747
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 12371442
Isoindolinone and indazole compounds for the degradation of EGFR
granted -
US 12370270
Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
granted -
US 12370264
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
granted -
US 12370192
Azole-fused pyridazin-3(2H)-one derivatives
granted -
US 12370267
Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA)
granted -
US 12370232
Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition
granted -
US 12370266
Polymer composite nanomaterial encapsulation system
granted -
US 12371685
PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof
granted -
US 12371665
Differentiation of pancreatic endocrine cells
granted -
US 12370257
Materials and methods of treating MHC-I-opathy risk haplotypes
granted -
US 12370206
Therapy for inhibition of single-stranded RNA virus replication
granted -
US 12370229
Methods of treating bladder cancer
granted -
US 12370142
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12371466
Chimeric antigen receptor and methods of use thereof
granted -
US 12370261
Chimeric peptides for antisense delivery
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted -
US 12371434
MLL1 inhibitors and anti-cancer agents
granted -
US 12370256
Activation of resident memory T cells for the treatment of cancer
granted -
US 12370195
Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
granted -
US 12370194
Metalloenzyme inhibitor compounds
granted -
US 12370175
Glucocorticoid receptor modulators to treat pancreatic cancer
granted -
US 12369604
Methods of inhibition with microbial strains and antibiotics
granted -
US 12371420
Polymorphs of Selinexor
granted -
US 12370196
Pharmaceutical compositions comprising meloxicam
granted -
US 12371503
Methods of treatment using a leptin receptor agonist antibody
granted -
US 12370188
Formulations of dazucorilant, a glucocorticoid receptor modulator
granted -
US 12371333
Purification of clinoptilolite
granted -
US 12371445
Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same
granted -
US 12371499
Method of treating cancer using anti-AV8 antibodies
granted -
WO 2025159142
COMPOSÉ HÉTÉROCYCLIQUE POUR INDUIRE LA DÉGRADATION DE LA PROTÉINE KRAS
granted -
CN 120418289
Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors
granted -
MX 2025007399
PROTEIN-BASED CONJUGATION CARRIERS
granted -
US 12378248
A1 adenosine receptor agonists and methods of use thereof
granted -
US 12377093
Pyruvate kinase activators for use in therapy
granted -
US 12378241
Pyridine derivative as FGFR and VEGFR dual inhibitors
granted -
US 12377186
Antimicrobial biopolymer compositions, methods of synthesis, and applications of use
granted -
US 12378231
Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof
granted -
US 12378280
Deoxynucleic guanidines (DNG)-modified oligonucleotides and methods of synthesizing deoxynucleic guanidine strands
granted -
US 12379385
Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function
granted -
US 12377051
Microspheres for extended, controlled release of therapeutic agents
granted -
US 12377069
Compounds, compositions, methods of using, and methods for preparing compounds
granted -
US 12377191
Chondroinductive peptides and compositions and methods of use thereof
granted -
US 12378195
Aminated psilocybin derivatives and methods of using
granted -
US 12377252
Implantation devices, system, and methods
granted -
US 12377078
Viral inhibitors, the synthesis thereof, and intermediates thereto
granted -
US 12377106
Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK
granted -
US 12378256
Heterocyclic compound
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.